ArticleLupus science & medicine2026
Glucocorticoid exposure and social support deficits as longitudinal predictors of long-term neuropsychiatric damage in SLE: insights from the LUMINA cohort (LXXXIII).
Article in Lupus science & medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
objectiveTo identify longitudinal predictors of neuropsychiatric damage in SLE and compare predictors of organic versus all neuropsychiatric outcomes.
methodsWe studied 657 patients from the multiethnic Lupus in Minorities: Nature vs Nurture cohort (5944 person-visit observations). Organic neuropsychiatric damage (seizures, cerebrovascular accident, neuropathy, transverse myelitis) and all neuropsychiatric damage (organic plus cognitive impairment/psychosis) were defined using the Systemic Lupus International Collaborating Clinic/American College of Rheumatology Damage Index. Random survival forests with time-varying covariates modelled 173 predictors. Feature importance was assessed by permutation methods and SHapley Additive exPlanations (SHAP).
results92 patients (14.0%) had organic and 197 (30.0%) had any neuropsychiatric damage; models were trained on incident events (48 and 90, respectively). Random survival forests achieved C-indices of 0.738 (organic) and 0.775 (all neuropsychiatric damage) outperforming Cox regression. For organic damage, glucocorticoid highest ever daily dose was the strongest predictor, followed by social support deficits and retirement status, exceeding disease activity measures. Tangible material support deficits specifically dominated the social support signal. SHAP dependence analysis suggested a model-derived inflection in risk contribution between approximately 40 and 60 mg/day, with current dose contributing approximately 2.8-fold more to model-predicted risk for all neuropsychiatric damage than for organic damage alone (mean |SHAP| 0.022 vs 0.008). For the secondary outcome, physician global assessment, fatigue and pain ranked highest, suggesting distinct predictor profiles for cognitive versus organic outcomes. Social determinants of health contributed independently of clinical severity.
conclusionsIn this exploratory analysis, glucocorticoid exposure and tangible social support deficits emerged as leading, potentially modifiable predictors of neuropsychiatric damage in SLE, often outranking disease activity measures, with implications for glucocorticoid stewardship, tangible-support screening and outcome-specific management. External validation in an independent contemporary cohort is required prior to clinical translation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.